This segment focuses on the research, development, and commercialization of novel therapeutics for various retinal diseases, including wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. The primary focus is on the lead product candidate, KSI-301, an anti-VEGF antibody biopolymer conjugate, currently in Phase IIb/III clinical trials. Research and development activities include ongoing clinical trials to evaluate the efficacy and safety of KSI-301. The company utilizes advanced molecular engineering and biopolymer conjugation technologies to enhance drug delivery and efficacy. The patient impact is significant, as these therapies aim to preserve and improve vision in patients suffering from vision-threatening conditions. Kodiak Sciences aims to gain a competitive advantage through its proprietary ABC Platform and innovative drug candidates. Future opportunities include expanding the pipeline to address other retinal diseases and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships with Nona Biosciences and AbCellera are in place to advance the discovery of novel multi-target antibodies for ophthalmic diseases.